Precision Oncology
Starts Here
Explore our advanced testing solutions, enhanced workflow optimizations, and collaborative partnerships to see what’s possible.
Partner With Us
We’re an Established Precision Oncology Leader
Delivering healthcare innovation with real impact, backed by over a decade of relentless research and development—our leadership speaks for itself.
Your Complete Testing Partner
From treatment selection to recurrence detection and progression monitoring, our tests provide the insights you need at every stage of the cancer continuum.
NEW Tissue-based molecular profiling with genomic, transcriptomic, and epigenomic insights.
The expanded liquid biopsy delivering genomic and epigenomic insights.
NEW Easy to order germline testing featuring a comprehensive hereditary cancer panel.
Fast, tissue-free MRD detection and monitoring.
Fast, FDA-approved liquid CGP featuring guideline-recommended biomarkers.
The first-and-only tissue-free treatment response monitoring solution.
Methylation-Based Technology Unlocks New Insights
At Guardant, we believe epigenomics — the core of our Guardant Infinity™ technology — will revolutionize how cancer is treated and managed. Only Guardant Infinity unlocks the power of both epigenomics and genomics with methylation-based technology.
See More
With Multidimensional Insights
Genomic Profiling
Methylation Profiling
Do More
With Exceptional Performance
Increased Sensitivity in Cancer Monitoring¹
Promoter Methylation²⁻⁴
Methylation Signatures²⁻⁴
Discover More
With Continous Innovations
Promoter Methylation Status
CHiP Annotation
HRD Score and Subtyping
Negative Predictor
HLA-Typing
Tumor of Origin & CUP Adjudication
Histologic Subtyping
Pharmacogenomics
Viral Status
Let’s Connect
Contact Guardant Key Accounts to see how partnering with our team can advance care for your patients.
